compound semaglutide shortage The GLP-1 drug is over. What's next for the compounders? The Semaglutide Shortage Is Ending:

Retatrutide changes this equation entirely

I'm Ayla, the founder, formulator, and CEO of FullWell

Want to walk through these questions in your own situation

As more individuals grapple with obesity and its associated health risks, this medication offers a beacon of hope, appealing to both healthcare providers and patients alike

Prior to the scheduled virtual appointment, the patient will receive a link to access the required intake documents, which are designed to collect information regarding current medications, daily dietary habits and previous medical conditions

Clinicians should consider prioritising review for people with type 2 diabetes on the affected GLP-1 RA preparation where: HbA1c greater than 86mmol/mol in the previous 3 to 6 months HbA1c greater than 86mmol/mol prior to starting the GLP1-RA HbA1c not recorded in the previous 6 months Urine albumin creatinine ratio (uACR) greater than 30mg/mmol Self-monitoring glucose readings (or Continuous Glucose Monitoring, where available) are persistently above individualised target range